{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:51:46Z","timestamp":1792281106959,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Bone and Joint Surgery"],"published-print":{"date-parts":[[2017,6,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The use of bisphosphonates has been reported to have potential beneficial effects on knee osteoarthritis, but existing studies have limitations. The purpose of this study was to examine the association of bisphosphonate use with the risk of undergoing total knee arthroplasty and with the consumption of pain medication among osteoporotic patients with knee osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We identified patients who were newly diagnosed with knee osteoarthritis among a cohort of patients with osteoporosis from 2009 to 2012 in the National Health Insurance Research Database in Taiwan. We further categorized these patients into 2 groups: those who were treated with bisphosphonates (bisphosphonate users) and those who were not treated with any anti-osteoporosis drug (nonusers). Bisphosphonate treatment adherence was calculated by the medication possession ratio (MPR) as the proportion of days of bisphosphonate treatment within a fixed duration; an MPR of \u226580% was considered high adherence. The primary and secondary outcomes of interest were undergoing total knee arthroplasty and the use of pain medication, respectively. Analyses using Cox proportional hazard models with propensity-score adjustment were performed to estimate the association between bisphosphonate use and the risk of undergoing total knee arthroplasty. The incremental change in the mean accumulated defined daily doses of pain medications among both bisphosphonate users and nonusers was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 16,276 bisphosphonate users and 123,791 nonusers of any anti-osteoporosis drug among the patients with osteoporosis who were newly diagnosed with osteoarthritis. Bisphosphonate use was significantly associated with a decreased risk of total knee arthroplasty (adjusted hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.69 to 0.83; p &lt; 0.001). In patients with a follow-up period of \u226524 months and an MPR of \u226580%, the effect size was significantly greater (adjusted HR, 0.66; p = 0.048). Over the 5 years of follow-up, we found a significantly greater decrease in the use of pain medication among bisphosphonate users than among nonusers (p &lt; 0.001; Chow test).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Among patients with osteoporosis and osteoarthritis, bisphosphonate use was associated with a significantly lower risk of total knee arthroplasty, especially in patients with high adherence and longer treatment duration. A lower consumption of pain medication was also found for bisphosphonate users among the patients with osteoporosis and osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>\n                      Therapeutic\n                      <jats:underline>Level III<\/jats:underline>\n                      . See Instructions for Authors for a complete description of levels of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.16.00385","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T11:32:29Z","timestamp":1496835149000},"page":"938-946","source":"Crossref","is-referenced-by-count":54,"title":["Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis"],"prefix":"10.2106","volume":"99","author":[{"given":"Shau-Huai","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Orthopedics, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin County, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy (C.-Y.W.) and School of Pharmacy (C.-Y.W., F.-L.L.W., and F.-Y.H.), College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Sen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics (R.-S.Y.) and Department of Pharmacy (F.-L.L.W. and F.-Y.H.), National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fe-Lin Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin County, Taiwan"},{"name":"Graduate Institute of Clinical Pharmacy (C.-Y.W.) and School of Pharmacy (C.-Y.W., F.-L.L.W., and F.-Y.H.), College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Orthopedics (R.-S.Y.) and Department of Pharmacy (F.-L.L.W. and F.-Y.H.), National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin County, Taiwan"},{"name":"Graduate Institute of Clinical Pharmacy (C.-Y.W.) and School of Pharmacy (C.-Y.W., F.-L.L.W., and F.-Y.H.), College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Orthopedics (R.-S.Y.) and Department of Pharmacy (F.-L.L.W. and F.-Y.H.), National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230810","doi-asserted-by":"crossref","first-page":"698709","DOI":"10.1155\/2012\/698709","article-title":"The global economic cost of osteoarthritis: how the UK compares","volume":"2012","author":"Chen","year":"2012","journal-title":"Arthritis."},{"issue":"12","key":"bib2-20230810","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1002\/art.24984","article-title":"Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data","volume":"60","author":"Kotlarz","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"2","key":"bib3-20230810","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines","volume":"16","author":"Zhang","year":"2008","journal-title":"Osteoarthritis Cartilage."},{"issue":"12","key":"bib4-20230810","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/art.10630","article-title":"Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study","volume":"46","author":"Bettica","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"3","key":"bib5-20230810","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00002281-199805000-00017","article-title":"The importance of subchondral bone in osteoarthrosis","volume":"10","author":"Burr","year":"1998","journal-title":"Curr Opin Rheumatol."},{"issue":"5","key":"bib6-20230810","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bone.2006.04.033","article-title":"Osteoclasts play a part in pain due to the inflammation adjacent to bone","volume":"39","author":"Nagae","year":"2006","journal-title":"Bone."},{"issue":"11","key":"bib7-20230810","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/art.20627","article-title":"The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis","volume":"50","author":"Carbone","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"8","key":"bib8-20230810","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2011-200970","article-title":"Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial","volume":"71","author":"Laslett","year":"2012","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"bib9-20230810","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10067-013-2338-8","article-title":"Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial","volume":"32","author":"Nishii","year":"2013","journal-title":"Clin Rheumatol."},{"issue":"3","key":"bib10-20230810","doi-asserted-by":"crossref","first-page":"R625","DOI":"10.1186\/ar1716","article-title":"Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]","volume":"7","author":"Spector","year":"2005","journal-title":"Arthritis Res Ther."},{"issue":"5","key":"bib11-20230810","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/annrheumdis-2012-202989","article-title":"Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative","volume":"73","author":"Laslett","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"bib12-20230810","first-page":"99","article-title":"Using Taiwan\u2019s national health insurance research databases for pharmacoepidemiology research","volume":"15","author":"Hsiao","year":"2007","journal-title":"J Food Drug Anal."},{"key":"bib13-20230810","doi-asserted-by":"crossref","first-page":"d7222","DOI":"10.1136\/bmj.d7222","article-title":"Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study","volume":"343","author":"Prieto-Alhambra","year":"2011","journal-title":"BMJ."},{"issue":"2","key":"bib14-20230810","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","article-title":"Impact of osteoporosis treatment adherence on fracture rates in North America and Europe","volume":"122","author":"Siris","year":"2009","journal-title":"Am J Med."},{"key":"bib15-20230810","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/PPA.S40736","article-title":"Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis","volume":"7","author":"Kozma","year":"2013","journal-title":"Patient Prefer Adherence."},{"issue":"4","key":"bib16-20230810","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bone.2011.12.021","article-title":"Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan","volume":"50","author":"Wade","year":"2012","journal-title":"Bone."},{"key":"bib18-20230810","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2307\/1910133","article-title":"Tests of equality between sets of coefficients in two linear regressions","volume":"28","author":"Chow","year":"1960","journal-title":"Econometrica."},{"issue":"9041","key":"bib19-20230810","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"issue":"22","key":"bib20-20230810","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med."},{"issue":"5","key":"bib21-20230810","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int."},{"issue":"9","key":"bib22-20230810","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00228-014-1708-8","article-title":"Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study","volume":"70","author":"Ghirardi","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"issue":"5","key":"bib23-20230810","first-page":"30","article-title":"[Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study]","volume":"85","author":"Alekseeva","year":"2013","journal-title":"Ter Arkh."},{"issue":"6","key":"bib24-20230810","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.joca.2007.10.002","article-title":"Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial","volume":"16","author":"Garnero","year":"2008","journal-title":"Osteoarthritis Cartilage."},{"issue":"2","key":"bib25-20230810","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/kel213","article-title":"A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients","volume":"46","author":"Buckland-Wright","year":"2007","journal-title":"Rheumatology (Oxford)."},{"issue":"8","key":"bib26-20230810","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00198-014-2738-x","article-title":"Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female Medicare beneficiaries","volume":"25","author":"Wang","year":"2014","journal-title":"Osteoporos Int."},{"issue":"1","key":"bib27-20230810","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jbmr.533","article-title":"Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence","volume":"27","author":"Sampalis","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"10","key":"bib28-20230810","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol."},{"key":"bib29-20230810","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ."},{"issue":"6","key":"bib30-20230810","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1532-5415.1997.tb01468.x","article-title":"The impact of aging and chronic disease on use of hospital and outpatient services in a large HMO: 1971-1991","volume":"45","author":"Haan","year":"1997","journal-title":"J Am Geriatr Soc."},{"issue":"5","key":"bib31-20230810","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Journal of Bone and Joint Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004623-201706070-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:37:14Z","timestamp":1787751434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004623-201706070-00006"}},"subtitle":["A Nationwide Cohort Study in Taiwan"],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.16.00385","relation":{},"ISSN":["0021-9355","1535-1386"],"issn-type":[{"value":"0021-9355","type":"print"},{"value":"1535-1386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}